DDW 2022 Conference Coverage


 

Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab and Infliximab in Biologic-Naive Patients With Ulcerative Colitis

111 views
June 7, 2022
Comments 0
Login to view comments. Click here to Login